Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

5.6%

3 terminated out of 54 trials

Success Rate

92.3%

+5.7% vs benchmark

Late-Stage Pipeline

6%

3 trials in Phase 3/4

Results Transparency

25%

9 of 36 completed with results

Key Signals

9 with results92% success

Data Visualizations

Phase Distribution

52Total
Not Applicable (7)
P 1 (41)
P 2 (1)
P 3 (3)

Trial Status

Completed36
Recruiting6
Not Yet Recruiting5
Unknown3
Terminated3
Withdrawn1

Trial Success Rate

92.3%

Benchmark: 86.6%

Based on 36 completed trials

Clinical Trials (54)

Showing 20 of 20 trials
NCT06633562Phase 1Terminated

A Study to Test the Effects of Nezavist at Different Doses in Healthy Adults

NCT07789327Phase 1Not Yet Recruiting

Phase 1/2 Clinical Study of HY07121 for Injection (Subcutaneous) in Patients With Advanced Solid Tumors

NCT07285967Phase 1Not Yet Recruiting

A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet

NCT05142592Phase 1Completed

Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors

NCT07663838Phase 1Not Yet Recruiting

A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)

NCT07660107Not ApplicableCompleted

Safety and Tolerability of Oral Supplementation With 1 mg of KGA-10 Daily (a Novel Environmentally-derived Mycolicibacterium) - a Pilot Study

NCT07016802Phase 1Recruiting

A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD)

NCT07286656Phase 1Recruiting

A Study of GensSci098 in Subjects With Graves' Disease

NCT06569758Phase 1Recruiting

A Study of GenSci098 in Subjects With Active Thyroid Eye Disease

NCT06243354Phase 1Recruiting

Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation

NCT06639256Phase 1Recruiting

Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors

NCT06770491Phase 1Completed

A Phase 1 Study of Y-3 in US Healthy Volunteers.

NCT06752122Phase 1Recruiting

Safety, Tolerability, and Pharmacokinetics of RCS-21 in Healthy Volunteers.

NCT06380270Not ApplicableCompleted

Evaluation of Safety and Human Tolerance of Oral Probiotic Streptococcus Salivarius eK12

NCT04693429Phase 1Completed

Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+

NCT06847698Phase 1Not Yet Recruiting

Single Ascending Dose and Multiple Ascending Dose Study of AVR-48

NCT05556291Completed

Combination of Ertugliflozin And Sitagliptin Efficacy, Safety & Tolerability (CEASE Diabetes) Study

NCT06879067Phase 1Completed

Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers

NCT05143905Phase 1Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants

NCT05633147Phase 1Completed

Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam

Scroll to load more

Research Network

Activity Timeline